A Mouse Model of Hepatocellular Carcinoma
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 71 of the 77 references it cites were found in a registry or an index.
Abstract
Most mouse models of hepatocellular carcinoma have expressed growth factors and oncogenes under the control of a liver-specific promoter. In contrast, we describe here the formation of liver tumors in transgenic mice overexpressing human fibroblast growth factor 19 (FGF19) in skeletal muscle. FGF19 transgenic mice had elevated hepatic alpha-fetoprotein mRNA as early as 2 months of age, and hepatocellular carcinomas were evident by 10 months of age. Increased proliferation of pericentral hepatocytes was demonstrated by 5-bromo-2'-deoxyuridine incorporation in the FGF19 transgenic mice before tumor formation and in nontransgenic mice injected with recombinant FGF19 protein. Areas of small cell dysplasia were initially evident pericentrally, and dysplastic/neoplastic foci throughout the hepatic lobule were glutamine synthetase-positive, suggestive of a pericentral origin. Consistent with chronic activation of the Wingless/Wnt pathway, 44% of the hepatocellular tumors from FGF19 transgenic mice had nuclear staining for beta-catenin. Sequencing of the tumor DNA encoding beta-catenin revealed point mutations that resulted in amino acid substitutions. These findings suggest a previously unknown role for FGF19 in hepatocellular carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, the therapeutic potential of FGF19 has been hindered by its effect on potential occurrence of HCC, since mice expressing an FGF19 transgene developed liver tumors while tumor FGF19 hepatic mRNA expression was an independent prognostic factor for overall and disease-free survival [259,260].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Given that mice expressing a FGF19 transgene develop hepatocellular carcinomas,14 the potential risk of tumorigenicity in patients treated with FXR agonists may need to be monitored.”
From NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) · cites this paper as [14]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the therapeutic potential of FGF19 has been hindered by its effect on potential occurrence of HCC, since mice expressing an FGF19 transgene developed liver tumors while tumor FGF19 hepatic mRNA expression was an independent prognostic factor for overall and disease-free survival [259,260].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [259]
Experimental — accuracy not yet measuredIn the citing paper
“However, the therapeutic potential of FGF19 is limited by concerns about tumorigenicity, as ectopic overexpression of FGF19 in mice results in the development of hepatocellular carcinoma.14”
From NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) · cites this paper as [14]
In the citing paper
“Similarly, expression of fibroblast growth factor 19 (FGF19) by skeletal muscle cells has been shown to induce hepatocellular carcinomas, which acquire somatic mutations in β-catenin (Ctnnb1).53”
From Paracrine roles of cellular senescence in promoting tumourigenesis (2018) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043 · cited 1×
“Primary cancer of the liver, or HCC, is the third most frequent cause of death by cancer in the world.(15) Consistent with the observation that oncogenes, growth factors, or viral genes are frequently up-regulated in human HCC, it is not surprising that overexpression of these genes in the liver also causes HCC in tra…”
Backgroundβ-catenin is a target for the ubiquitin–proteasome pathway
Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3797 · Cited by 2,529
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 2,272
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456 · cited 1×
“Inflammation is also prominent in mice lacking the mdr2 gene that results in failure to transport phosphatidyl choline into the bile and inability to emulsify biliary components leading to inflammation, hepatocellular proliferation, and HCC by 18 months of age.(30) Similarly, mice lacking peroxisomal fatty acyl-CoA ox…”
BackgroundMichael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., & Kahn, C. R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00015-8 · Cited by 1,296
Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D., & Moon, R. T. (1996) · Genes & Development · doi:10.1101/gad.10.12.1443 · Cited by 1,165
Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas
Coste, A. D. L., Romagnolo, B., Billuart, P., Renard, C.-A., Buendia, M.-A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8847 · Cited by 1,121
Fausto, N. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80412-2 · Cited by 1,022
Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents
Beranek, D. T. (1990) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/0027-5107(90)90173-2 · Cited by 899 · cited 2×
“For example, diethylnitrosamine induces pericentral foci of small dysplastic hepatocytes(55,56) and acts by ethylating nucleophilic sites in DNA.(57) Diethylnitrosamine-induced HCCs are also glutamine synthetase-positive suggesting that the neoplasFigure 5.”
Background
Cited by
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
“Furthermore, wild-type mice that were injected with FGF-19 for 6 days had an increase in hepatocellular proliferation (26).”
BackgroundThe FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Metadata
- Authors
- Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., Stinson, J., Stewart, T., & French, D. M.
- Affiliations
- Genentech (US)
- ORCID
- Tsai, Siao Ping
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2002-06
- Volume
- 160
- Issue
- 6
- Pages
- 2295-2307
- ISSN
- 0002-9440 (ISSN-L)
- PMC
- PMC1850847
- OpenAlex
- W1539520316
- Cited by
- 359
- References
- 77
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 18 · 2023: 14 · 2022: 21 · 2021: 24 · 2020: 30 · 2019: 29 · 2018: 29 · 2017: 22 · 2016: 18 · 2015: 29 · 2014: 16 · 2013: 14 · 2012: 24
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- American Journal Of Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatocellular carcinoma, FGF19, transgenic mice, alpha-fetoprotein, hepatocyte proliferation, glutamine synthetase, β-catenin, Wnt signaling, CTNNB1 mutation, tumor origin
- MeSH terms
- Amino Acid Sequence, Animals, Bromodeoxyuridine, Cell Division, Cytoskeletal Proteins, Disease Models, Animal, DNA, Neoplasm, Enzyme-Linked Immunosorbent Assay, Fibroblast Growth Factors, Humans, Immunohistochemistry, Liver, Liver Neoplasms, Experimental, Mice, Transgenic, Molecular Sequence Data, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Trans-Activators, Receptors, Fibroblast Growth Factor, Muscle, Skeletal, Amino Acid Substitution, Zebrafish Proteins, Wnt Proteins, beta Catenin, Mice, Receptor, Fibroblast Growth Factor, Type 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Mouse Model of Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1016/s0002-9440(10)61177-7
- The paper
- Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., Stinson, J., Stewart, T., & French, D. M. (2002). A Mouse Model of Hepatocellular Carcinoma. The American Journal of Pathology. https://doi.org/10.1016/s0002-9440(10)61177-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.